Diane P Hanger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3853686/publications.pdf

Version: 2024-02-01

99 papers	9,946 citations	41344 49 h-index	45317 90 g-index
122 all docs	122 docs citations	122 times ranked	10590 citing authors

#	Article	IF	Citations
1	Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in Molecular Medicine, 2009, 15, 112-119.	6.7	778
2	Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neuroscience Letters, 1992, 147, 58-62.	2.1	690
3	Roles of tau protein in health and disease. Acta Neuropathologica, 2017, 133, 665-704.	7.7	639
4	Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Reports, 2013, 14, 389-394.	4.5	510
5	Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Current Biology, 1994, 4, 1077-1086.	3.9	448
6	Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis. Journal of Biological Chemistry, 2007, 282, 23645-23654.	3.4	387
7	New Phosphorylation Sites Identified in Hyperphosphorylated Tau (Paired Helical Filamentâ€Tau) from Alzheimer's Disease Brain Using Nanoelectrospray Mass Spectrometry. Journal of Neurochemistry, 1998, 71, 2465-2476.	3.9	330
8	The Importance of Tau Phosphorylation for Neurodegenerative Diseases. Frontiers in Neurology, 2013, 4, 83.	2.4	312
9	Astrocytes are important mediators of AÎ²-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death and Disease, 2011, 2, e167-e167.	6.3	304
10	The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy. Current Biology, 2017, 27, 371-385.	3.9	287
11	Î±-Synuclein binds to the ERâ€“mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production. Acta Neuropathologica, 2017, 134, 129-149.	7.7	262
12	<scp>ALS</scp> / <scp>FTD</scp> â€associated <scp>FUS</scp> activates <scp>GSK</scp> â€3Î² to disrupt the <scp>VAPB</scp> â€“ <scp>PTPIP</scp> 51 interaction and <scp>ER</scp> â€“mitochondria associations. EMBO Reports, 2016, 17, 1326-1342.	4.5	201
13	Phosphorylation Regulates Tau Interactions with Src Homology 3 Domains of Phosphatidylinositol 3-Kinase, Phospholipase CÎ³1, Grb2, and Src Family Kinases. Journal of Biological Chemistry, 2008, 283, 18177-18186.	3.4	198
14	Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathology and Applied Neurobiology, 2003, 29, 288-302.	3.2	194
15	Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase. Journal of Neuroscience, 2005, 25, 6584-6593.	3.6	168
16	Parkinson's disease Î±-synuclein mutations exhibit defective axonal transport in cultured neurons. Journal of Cell Science, 2004, 117, 1017-1024.	2.0	163
17	A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology, 2014, 76, 1-8.	4.1	160
18	Collapsin response mediator proteinâ€2 hyperphosphorylation is an early event in Alzheimerâ€™s disease progression. Journal of Neurochemistry, 2007, 103, 1132-1144.	3.9	158

#	Article	IF	Citations
19	Induction of neuronal death by Î±â€synuclein. European Journal of Neuroscience, 2000, 12, 3073-3077.	2.6	151
20	Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB Journal, 2008, 22, 3186-3195.	0.5	142
21	Molecular motors implicated in the axonal transport of tau and Î±-synuclein. Journal of Cell Science, 2005, 118, 4645-4654.	2.0	141
22	Tau phosphorylation affects its axonal transport and degradation. Neurobiology of Aging, 2013, 34, 2146-2157.	3.1	136
23	Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiology of Aging, 2012, 33, 431.e27-431.e38.	3.1	117
24	Familial Danish Dementia: A Novel Form of Cerebral Amyloidosis Associated with Deposition of Both Amyloid-Dan and Amyloid-Beta. Journal of Neuropathology and Experimental Neurology, 2002, 61, 254-267.	1.7	116
25	Membraneâ€bound Î²â€amyloid oligomers are recruited into lipid rafts by a fynâ€dependent mechanism. FASEB Journal, 2008, 22, 1552-1559.	0.5	114
26	Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB Journal, 2009, 23, 739-750.	0.5	113
27	Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimerâ€™s disease brain. Acta Neuropathologica Communications, 2016, 4, 34.	5.2	100
28	Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Neuroscience Letters, 1997, 230, 49-52.	2.1	97
29	PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3Î². FEBS Letters, 1994, 349, 359-364.	2.8	92
30	Sites of phosphorylation in tau and factors affecting their regulation. Biochemical Society Symposia, 2001, 67, 73-80.	2.7	91
31	Anti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy. Frontiers in Psychiatry, 2010, 1, 136.	2.6	91
32	Familial Alzheimer's disease with the amyloid precursor protein position 717 mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. Neuroscience Letters, 1992, 137, 221-224.	2.1	87
33	Mediators of tau phosphorylation in the pathogenesis of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2009, 9, 1647-1666.	2.8	82
34	Functional Implications of Glycogen Synthase Kinase-3-Mediated Tau Phosphorylation. International Journal of Alzheimer's Disease, 2011, 2011, 1-11.	2.0	82
35	Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain, 2002, 125, 969-975.	7.6	80
36	Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS Journal, 2011, 278, 2927-2937.	4.7	78

#	Article	IF	Citations
37	Astrocytes and neuroinflammation in Alzheimer's disease. Biochemical Society Transactions, 2014, 42, 1321-1325.	3.4	76
38	The Microtubule-Associated Protein Tau is Also Phosphorylated on Tyrosine. Journal of Alzheimer's Disease, 2009, 18, 1-9.	2.6	75
39	Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a â€œP301Lâ€•tau knockin mouse. Neurobiology of Aging, 2012, 33, 621.e1-621.e15.	3.1	75
40	Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of Nâ€terminally cleaved tau containing four microtubuleâ€binding repeats. Journal of Neurochemistry, 2008, 105, 2343-2352.	3.9	73
41	Kinase activities increase during the development of tauopathy in htau mice. Journal of Neurochemistry, 2007, 103, 2256-2267.	3.9	69
42	Functional implications of the association of tau with the plasma membrane. Biochemical Society Transactions, 2010, 38, 1012-1015.	3.4	64
43	Quantitative analysis of tau isoform transcripts in sporadic tauopathies. Molecular Brain Research, 2005, 137, 104-109.	2.3	60
44	Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2016, 4, 49.	5.2	60
45	Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding. Prion, 2009, 3, 78-83.	1.8	59
46	The ultrastructural distribution of alpha-synuclein-like protein in normal mouse brain. Brain Research, 2004, 1004, 61-72.	2.2	58
47	Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons. Neurobiology of Disease, 2016, 85, 1-10.	4.4	57
48	Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Neuroscience Letters, 1996, 219, 167-170.	2.1	53
49	The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Letters, 2002, 531, 538-542.	2.8	52
50	Tau cleavage and tau aggregation in neurodegenerative disease. Biochemical Society Transactions, 2010, 38, 1016-1020.	3.4	51
51	Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures. Cell Death and Disease, 2017, 8, e2671-e2671.	6.3	50
52	Oxidative Stress Induces Dephosphorylation of Ï„ in Rat Brain Primary Neuronal Cultures. Journal of Neurochemistry, 1997, 68, 1590-1597.	3.9	49
53	Prostate-derived Sterile 20-like Kinases (PSKs/TAOKs) Phosphorylate Tau Protein and Are Activated in Tangle-bearing Neurons in Alzheimer Disease. Journal of Biological Chemistry, 2013, 288, 15418-15429.	3.4	49
54	Fluconazole and testosterone: in vivo and in vitro studies. Antimicrobial Agents and Chemotherapy, 1988, 32, 646-648.	3.2	46

#	Article	IF	Citations
55	The microtubule-associated protein tau is phosphorylated by Syk. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 188-192.	4.1	46
56	Intracellular and Extracellular Roles for Tau in Neurodegenerative Disease. Journal of Alzheimer's Disease, 2014, 40, S37-S45.	2.6	45
57	A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies. Acta Neuropathologica Communications, 2018, 6, 37.	5.2	44
58	Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. Brain, 2016, 139, 2290-2306.	7.6	43
59	Modulation of PHF-like tau phosphorylation in cultured neurones and transfected cells. Neurobiology of Aging, 1995, 16, 389-397.	3.1	41
60	Advances in tau-based drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 797-810.	5.0	39
61	Calpain cleavage and inactivation of the sodium calcium exchangerâ€3 occur downstream of <scp>A</scp>Î² in <scp>A</scp>lzheimer's disease. Aging Cell, 2014, 13, 49-59.	6.7	38
62	Transgenic Mouse Models of Tauopathy in Drug Discovery. CNS and Neurological Disorders - Drug Targets, 2010, 9, 403-428.	1.4	36
63	Characterisation of tau in the human and rodent enteric nervous system under physiological conditions and in tauopathy. Acta Neuropathologica Communications, 2018, 6, 65.	5.2	32
64	NUB1 modulation of GSK3Î² reduces tau aggregation. Human Molecular Genetics, 2012, 21, 5254-5267.	2.9	29
65	Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3Î². Biology Open, 2014, 3, 1-11.	1.2	27
66	Autopsy-Confirmed Familial Early-Onset Alzheimer Disease Caused by the L153V Presenilin 1 Mutation. Archives of Neurology, 2001, 58, 953.	4.5	26
67	Hippocampal neurophysiology is modified by a disease-associated C-terminal fragment of tau protein. Neurobiology of Aging, 2017, 60, 44-56.	3.1	26
68	Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase mos. Neurobiology of Aging, 1996, 17, 235-241.	3.1	24
69	Isolation of detergent resistant microdomains from cultured neurons: detergent dependent alterations in protein composition. BMC Neuroscience, 2010, 11, 120.	1.9	24
70	Tau pathology in a case of familial Alzheimer's disease with a valine to glycine mutation at position 717 in the amyloid precursor protein. Neuroscience Letters, 1992, 145, 178-180.	2.1	23
71	Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice. Neurobiology of Aging, 2016, 39, 1-18.	3.1	23
72	Phosphorylation of Tau by Cyclic-AMP-Dependent Protein Kinase. Dementia and Geriatric Cognitive Disorders, 1993, 4, 256-263.	1.5	21

#	Article	IF	Citations
73	Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Molecular Brain Research, 2004, 121, 95-101.	2.3	20
74	Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 7434.	3.3	20
75	Chicken synucleins: cloning and expression in the developing embryo. Mechanisms of Development, 2000, 99, 195-198.	1.7	19
76	Bridging integrator 1 protein loss in Alzheimerâ€™s disease promotes synaptic tau accumulation and disrupts tau release. Brain Communications, 2020, 2, .	3.3	18
77	Key issues in the acquisition and analysis of qualitative and quantitative mass spectrometry data for peptide-centric proteomic experiments. Amino Acids, 2012, 43, 1075-1085.	2.7	16
78	A pathogenic tau fragment compromises microtubules, disrupts insulin signaling and induces the unfolded protein response. Acta Neuropathologica Communications, 2019, 7, 2.	5.2	16
79	Synaptic Localisation of Tau. Advances in Experimental Medicine and Biology, 2019, 1184, 105-112.	1.6	16
80	The Kinase Fyn As a Novel Intermediate in l-DOPA-Induced Dyskinesia in Parkinsonâ€™s Disease. Molecular Neurobiology, 2018, 55, 5125-5136.	4.0	15
81	Considerations for future tau-targeted therapeutics: can they deliver?. Expert Opinion on Drug Discovery, 2020, 15, 265-267.	5.0	11
82	Quantitation of glycogen synthase kinaseâ€3 sensitive proteins in neuronal membrane rafts. Proteomics, 2009, 9, 3022-3035.	2.2	9
83	The Disease Associated Tau35 Fragment has an Increased Propensity to Aggregate Compared to Full-Length Tau. Frontiers in Molecular Biosciences, 2021, 8, 779240.	3.5	8
84	Molecular pathology of Alzheimer's disease in sporadic and familial Alzheimer's disease with mutations in the amyloid precursor protein. Biochemical Society Transactions, 1992, 20, 642-645.	3.4	7
85	Characterization of a Partial cDNA Specific for the High Molecular Weight Microtubule-Associated Protein MAP2 That Encodes Epitopes Shared with Paired Helical Filaments of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1990, 1, 304-315.	1.5	1
86	Familial Alzheimer's disease with an APP717 point mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. Neurobiology of Aging, 1992, 13, S57.	3.1	1
87	PHOSPHORYLATION OF TAU BY GLYCOGEN SYNTHASE KINASE-3Î² IN VITRO PRODUCES SPECIES WITH SIMILAR ELECTROPHORETIC AND IMMUNOGENIC PROPERTIES TO PHF-TAU FROM AIZHEIMERS DISEASE BRAIN. Biochemical Society Transactions, 1995, 23, 45S-45S.	3.4	1
88	Editorial: Tau Propagation Mechanisms: Cell Models, Animal Models, and Beyond. Frontiers in Neuroscience, 2020, 14, 456.	2.8	1
89	HCN channelopathy couples diseaseâ€associated tau to synaptic dysfunction. Alzheimer's and Dementia, 2021, 17, e058346.	0.8	1
90	Autophagy and lysosomal defects in cells expressing diseaseâ€associated tau. Alzheimer's and Dementia, 2021, 17, e058299.	0.8	1

#	Article	IF	Citations
91	P3-258 Molecular motors implicated in the fast axonal transport of tau. Neurobiology of Aging, 2004, 25, S428.	3.1	0
92	P1-115: IDENTIFICATION OF THE BINDING SITE BETWEEN TAU AND FYN: CONSEQUENCES FOR TAU RELEASE?. , 2014, 10, P343-P343.		0
93	P1-116: ASTROCYTE ACTIVATION INFLUENCES THE DEVELOPMENT OF TAUOPATHY. , 2014, 10, P343-P343.		0
94	P3-054: The amyloid-binding agent bta-eg4 reduces pathological tau species in a novel organotypic 3xTg-AD brain slice culture model that recapitulates key in vivo degenerative phenotypes. , 2015, 11, P639-P639.		0
95	P1â€155: Postâ€Mortem Brain Tissue Characterisation of Inflammatory and Pathological Hallmarks of Alzheimerâ€™s Disease During Disease Progression. Alzheimer's and Dementia, 2016, 12, P462.	0.8	0
96	[P1â€“223]: FUNCTIONAL ROLES FOR TAOK KINASES IN THE DEVELOPMENT OF TAU PATHOLOGY IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P328.	0.8	0
97	[F3â€“07â€“03]: ACTIVITYâ€DEPENDENT TAU RELEASE: IMPLICATIONS FOR TAU PROPAGATION. Alzheimer's and Dementia, 2017, 13, P888.	0.8	0
98	Defects in the autophagy lysosomal pathway in a cell model of diseaseâ€associated tau. Alzheimer's and Dementia, 2021, 17, e051303.	0.8	0
99	Self-assembly and cellular effect of tau35, a disease-associated tau fragment.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052072.	0.8	0